Energize Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.55 M
as on 16-11-2024
- Revenue 249.77%
(FY 2023)
- Profit -79.75%
(FY 2023)
- Ebitda -58.39%
(FY 2023)
- Net Worth 48.08%
(FY 2023)
- Total Assets 138.52%
(FY 2023)
About Energize Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.55 M.
Dattatraya Dake, Rupali Dake, and Babasaheb Dake serve as directors at the Company.
- CIN/LLPIN
U74900PN2013PTC149144
- Company No.
149144
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Energize Pharmaceuticals Private Limited offer?
Energize Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Herbal Capsules.
Who are the key members and board of directors at Energize Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dattatraya Dake  | Director | 14-Oct-2013 | Current |
| Rupali Dake | Director | 11-Apr-2019 | Current |
| Babasaheb Dake | Director | 11-Apr-2019 | Current |
Financial Performance of Energize Pharmaceuticals.
Energize Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 249.77% increase. The company also saw a substantial fall in profitability, with a 79.75% decrease in profit. The company's net worth Soared by an impressive increase of 48.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Energize Pharmaceuticals?
In 2023, Energize Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gummies And Gummies Nutrient Private LimitedActive 1 year 4 monthsDattatraya Dake and Rupali Dake are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Feb 2020 | ₹4.55 M | Open |
How Many Employees Work at Energize Pharmaceuticals?
Energize Pharmaceuticals has a workforce of 42 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Energize Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Energize Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
